Your browser is no longer supported. Please, upgrade your browser.
ANIK Anika Therapeutics, Inc. daily Stock Chart
ANIK [NASD]
Anika Therapeutics, Inc.
Index- P/E18.27 EPS (ttm)1.99 Insider Own0.90% Shs Outstand14.20M Perf Week0.67%
Market Cap507.53M Forward P/E31.32 EPS next Y1.16 Insider Trans-3.04% Shs Float13.99M Perf Month9.66%
Income28.50M PEG1.83 EPS next Q-0.25 Inst Own95.10% Short Float15.08% Perf Quarter16.14%
Sales125.30M P/S4.05 EPS this Y48.40% Inst Trans-0.05% Short Ratio13.37 Perf Half Y-26.95%
Book/sh20.68 P/B1.76 EPS next Y2420.00% ROA8.50% Target Price51.00 Perf Year-9.94%
Cash/sh6.61 P/C5.50 EPS next 5Y10.00% ROE10.20% 52W Range22.01 - 75.71 Perf YTD-29.93%
Dividend- P/FCF18.73 EPS past 5Y-5.50% ROI8.80% 52W High-52.02% Beta1.15
Dividend %- Quick Ratio4.80 Sales past 5Y1.70% Gross Margin71.60% 52W Low65.06% ATR1.84
Employees154 Current Ratio6.20 Sales Q/Q43.30% Oper. Margin28.60% RSI (14)55.96 Volatility4.19% 5.09%
OptionableYes Debt/Eq0.00 EPS Q/Q28.20% Profit Margin22.70% Rel Volume0.69 Prev Close35.36
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout0.00% Avg Volume157.77K Price36.33
Recom2.00 SMA202.70% SMA506.43% SMA200-17.01% Volume109,179 Change2.74%
May-08-20Downgrade Barrington Research Outperform → Mkt Perform
Jan-21-20Upgrade Sidoti Neutral → Buy $61
Jan-10-20Upgrade First Analysis Sec Outperform → Strong Buy $65
Nov-05-19Initiated BWS Financial Sell $29
Sep-24-19Reiterated Barrington Research Outperform $49 → $58
Sep-23-19Downgrade First Analysis Sec Strong Buy → Outperform $54
Jul-25-19Upgrade First Analysis Sec Neutral → Strong Buy $37 → $54
Feb-22-19Downgrade Sidoti Buy → Neutral $56 → $41
Feb-22-19Downgrade First Analysis Sec Outperform → Neutral $41 → $37
Jul-27-18Upgrade Barrington Research Mkt Perform → Outperform $48
Jun-20-18Downgrade First Analysis Sec Overweight → Equal-Weight $45 → $34
Jun-20-18Downgrade Barrington Research Outperform → Mkt Perform
May-04-18Upgrade Barrington Research Mkt Perform → Outperform $39
Feb-23-18Downgrade Barrington Research Outperform → Mkt Perform
Jan-24-18Upgrade First Analysis Sec Equal-Weight → Overweight $45 → $68
Oct-27-17Reiterated Barrington Research Outperform $53 → $57
May-09-16Upgrade Singular Research BUY - Long-Term → Buy $60
Apr-27-16Downgrade Northland Capital Outperform → Market Perform
Feb-26-16Reiterated Barrington Research Outperform $45 → $49
Oct-12-15Initiated Barrington Research Outperform $39
Jun-23-20 11:50AM  
Jun-02-20 04:05PM  
May-12-20 04:05PM  
May-08-20 11:00PM  
12:00PM  
May-07-20 04:05PM  
May-01-20 06:34AM  
Apr-28-20 11:40AM  
Apr-27-20 08:30AM  
Apr-23-20 04:05PM  
Apr-08-20 04:05PM  
Apr-02-20 12:45PM  
Mar-26-20 06:12AM  
Mar-11-20 07:51AM  
Mar-04-20 08:30AM  
Feb-27-20 07:52AM  
Feb-21-20 07:46AM  
Feb-20-20 07:15PM  
04:05PM  
Feb-13-20 12:31PM  
Feb-12-20 04:05PM  
Feb-06-20 05:14PM  
Feb-04-20 05:38AM  
Feb-03-20 04:30PM  
Jan-29-20 04:30PM  
Jan-24-20 04:05PM  
Jan-13-20 03:00PM  
Jan-08-20 11:47AM  
Jan-06-20 08:30AM  
Dec-30-19 08:22AM  
Dec-24-19 08:57AM  
Dec-20-19 09:28AM  
Dec-19-19 11:35AM  
10:18AM  
10:02AM  
Dec-17-19 10:25AM  
Dec-16-19 03:44PM  
09:46AM  
08:42AM  
08:05AM  
Dec-13-19 09:25AM  
Dec-12-19 03:19PM  
02:34PM  
09:36AM  
Dec-11-19 04:11PM  
02:42PM  
10:06AM  
08:40AM  
Dec-10-19 09:26AM  
08:30AM  
Dec-09-19 04:31PM  
04:03PM  
08:36AM  
Dec-06-19 09:26AM  
Dec-05-19 03:53PM  
10:02AM  
09:07AM  
Dec-04-19 10:25AM  
Dec-03-19 10:45AM  
09:16AM  
08:59AM  
Dec-02-19 10:22AM  
Nov-28-19 08:10AM  
Nov-27-19 09:00AM  
03:32AM  
03:28AM  
Nov-25-19 09:18AM  
Nov-22-19 09:45AM  
Nov-21-19 10:24AM  
09:54AM  
08:00AM  
Nov-20-19 09:50AM  
Nov-19-19 09:40AM  
09:36AM  
Nov-18-19 05:25PM  
10:27AM  
Nov-15-19 10:02AM  
09:10AM  
08:57AM  
08:30AM  
Nov-14-19 10:20AM  
09:00AM  
08:27AM  
Nov-13-19 09:05AM  
08:00AM  
Nov-12-19 09:52AM  
Nov-09-19 03:54PM  
Nov-08-19 10:08AM  
Nov-07-19 11:26AM  
11:20AM  
Nov-06-19 11:24AM  
Nov-05-19 04:05PM  
11:45AM  
Nov-04-19 11:18AM  
11:08AM  
05:56AM  
Nov-01-19 02:49PM  
07:45AM  
Oct-31-19 12:40PM  
12:33PM  
Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Loerop JamesEVP Business DevelopmentJul 09Sale35.151,24443,7271,756Jul 10 04:06 PM
Blanchard Cheryl RPresident, CEO, DirectorApr 26Option Exercise0.004,231011,697Apr 28 06:41 PM
LAND RAYMOND JDirectorFeb 26Sale42.682,700115,23613,399Feb 27 06:54 PM
Cheung SylviaChief Financial OfficerNov 08Sale59.7120,0001,194,20047,741Nov 08 05:40 PM
Cheung SylviaChief Financial OfficerNov 06Option Exercise6.3635,000222,60071,422Nov 08 05:40 PM
Larsen Glenn R.DirectorAug 28Sale57.214,355249,1507,590Aug 30 04:05 PM
Bower Joseph L.DirectorAug 20Sale55.571,994110,80743,010Aug 22 04:05 PM
Thompson Jeffery SDirectorAug 08Sale56.664,843274,4046,842Aug 12 04:06 PM
LAND RAYMOND JDirectorJul 29Sale55.443,000166,32011,992Jul 30 04:06 PM